North America Vulvovaginal Candidiasis Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Oral, Intravenous and Topical), By Drug Class, By Country and Growth Forecast, 2022 - 2028
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America Vulvovaginal Candidiasis Treatment Market
Market Report Description
The North America Vulvovaginal Candidiasis Treatment Market would witness market growth of 3.9% CAGR during the forecast period (2022-2028).
The vaginal cultures should be performed for the women with negative results but have symptoms of VVC and proper treatment is required for those with positive results. Empiric treatment is considered appropriate if candida cultures cannot be performed. Most of the PCR tests for yeasts are not approved by FDA, because of this, the providers should be familiar with the performance characteristics of the test they are using.
Recurring VVC condition, which is defined as three or more episodes of having VVC symptoms in a year, affects more the 5% of women which also causes a substantial economic concern. Recurrence of vulvovaginal candidiasis could be idiopathic or secondary that is related to continuing diabetes, antibiotic use, or other such factors.
In most cases, recurrent VVC that is caused by C. Albicans could be treated by short-duration oral and topical azole therapies. Although to maintain clinical & mycologic control longer duration of initial therapy is suggested by gynecologists. An example of longer duration therapy is either 7–14 days of topical therapy or an oral dose of 100 mg, 150-mg, and 200 mg of fluconazole every third day three times which mean day 1, 4, and 7.
The risk of women with HIV infection risk of vulvovaginal candidiasis is high. Women with HIV are more prevalent to have white adherent vaginal discharge, mucosal itching & burning. Furthermore, women with advanced immunosuppression could have VVC severe and recurrent episodes of VVC. As a result of the high prevalence of HIV in the region, the market for vulvovaginal candidiasis treatment will expand during the forecast period.
The US market dominated the North America Vulvovaginal Candidiasis Treatment Market by Country in 2021; thereby, achieving a market value of $345.8 million by 2028. The Canada market is experiencing a CAGR of 6.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 5.4% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Oral, Intravenous and Topical. Based on Drug Class, the market is segmented into Fluconazole, Clotrimazole, Terconazole, Terbinafine, Nystatin, Ketoconazole and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Route of Administration
By Drug Class
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Bayer AG
- Bristol Myers Squibb Company
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
- Basilea Pharmaceutica Ltd.
- Scynexis, Inc.
- Grupo Ferrer Internacional S.A.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free